Phase III Study Results Show Effectiveness of ED Pills
“We are especially pleased by the results of this drawing, considering that cialis demonstrated welfare in men with all degrees of ED, including those with severe cases,” said Dr. Gerald Brock, of St. Joseph’s Welfare Building, Administrative division of Urology, INSTANCE OFCanadian province, Canada.
Tadalafil Treats Erectile Dysfunction
Laurie Barclay, MD May 31, 2007 — tadalafil (Cialis), a selective phosphodiesterase type 5 inhibitor, treats erectile dysfunction (ED) with little adverse cardiovascular consequence, according to new clinical data presented May 25 at the 97th reference confluence of the English Urological Tie in Orlando, Florida.
“Cialis was statistically scrapper to medicament in enabling men with ED to have successful congress at 24 or 36 period after taking the drug and showed a consistent appearance at both time points,” source Raymond Rosen, PhD, from Robert Wood INSTANCE OFPresident of the United States Medical Body in Piscataway, NJ, says in a news conclusion. “The temporal property of potency did not appear to consequence the optical phenomenon or grimness of side effects.”
In a period III, randomized, clinical musical composition, 348 men with mild-to-severe ED received tadalafil 20 mg or medicament over an 8-week geologic time.
Viagra vs Levitra
Viagra vs Levitra – Giving Men More Alternatives
Viagra is the leading erectile dysfunction medicine for men, what with its twenty plus years of excellent track record and safety in use. Young erectile dysfunction medicine like Levitra came out twenty years after the release of Viagra to challenge the “leader.” Can Levitra meet up for the challenge? Viagra vs. Levitra – which will work best for you?
Viagra and Levitra have different pharmacokinetics yet they work in the same way. Viagra’s main chemical component is Sildenafil Citrate while Levitra is Vardenafil. However, these two erectile dysfunction medicines are both PDE-5 inhibitors that block enzyme responsible for erectile dysfunction.
Schering-Plough’s Comments
Julie Lux, a spokeswoman for Schering-Plough, tells WebMD:
“We support the FDA’s decision to adopt new prescribing information regarding PDE-5 inhibitors [Viagra, Cialis or Levitra] and NAION. In addition, we continue to confer with other regulatory authorities worldwide and we constantly monitor product safety reports and work closely with worldwide regulatory authorities including the FDA to ensure that appropriate product information is shared with physicians and their patients.
“We recently received one spontaneous report of NAION occurring in a man taking Levitra,” Lux continues.
Lilly’s Response
Cialis is marketed by Lilly ICOS. Levitra is co-marketed by GlaxoSmithKline and Schering-Plough. Those companies — and Pfizer — are WebMD sponsors.
Lilly spokeswoman Kindra Strupp tells WebMD that on May 20 “there was a change to the postmarketing adverse events section … that comes toward the end of the [Cialis] label.
“There were a couple of items that were included under the ophthalmologic events section, which included NAION,” Strupp continues.
“The FDA came back and for all the sponsors there would be precautionary language around NAION,” says Strupp.